Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant hormone therapy comparison after radical prostatectomy in high-risk prostate cancer
ChiCTR-TRC-10001866Phase 2Completed
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bicalutamide in prostate cancer (PCa) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: 2-year biochemical progression-free survival. Started May 2010; status: completed.
02
Drugs
bicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR-TRC-10001866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001866.